Medical-related business turns profitable
First written in FY2017-Q2. 17 of 31 entries say "Advanced", first in FY2017-Q3. Latest entry: 2026-08-06.
Nihon Trim moved to the "Worse" side of this theme in 2025.
The whole theme swung hardest in 2023: 2 of 9 companies on the "Worse" side.
2 other companies' latest entry also says "Mitigated".
- 2026-08-06MitigatedEarnings
「Revenue from the medical-related business was ¥745 million, down 1.0% year on year, while segment profit was ¥68 million, up 144.7%.」
The medical-related business reported lower revenue but a 144.7% year-on-year increase in segment profit. - FY2026WorsenedAnnual report
「Revenue from the medical-related business was ¥3,024 million, up 4.4% year on year, while segment profit was ¥228 million, down 41.3%.」
The healthcare-related business recorded higher revenue, while segment profit was ¥228 million, down 41.3% year on year, resulting in a wider decline in profit. - 2026-05-13WorsenedEarnings
「Revenue from the medical-related business was ¥3,024 million, up 4.4% year on year, while segment profit was ¥228 million, down 41.3%.」
The medical-related business posted higher revenue but a 41.3% year-on-year decline in segment profit, indicating continued deterioration in profitability from FY2026 H1 through the full year. - FY2026-H1WorsenedAnnual report
「As a result, revenue from the healthcare-related business was ¥1,539 million, up 8.5% year on year, while segment profit was ¥107 million, down 49.9%. The decline in segment profit was attributable to increased investment in personnel and the restructuring of the sales organization at ステムセル研究所, as well as expenses related to launching the business in Singapore.」
The healthcare-related business recorded higher revenue, while segment profit declined 49.9% year on year. Increased investment in personnel, the restructuring of the sales organization and costs associated with launching the Singapore business were cited as factors behind the decline in profit. - FY2024AdvancedAnnual report
「Revenue from the healthcare-related business was ¥2,636 million, up 15.3% year on year, and segment profit was ¥392 million, up 58.1%.」
For the full year, the healthcare-related business posted revenue of ¥2,636 million and segment profit of ¥392 million, with continued growth in both revenue and profit. - FY2024-Q3AdvancedAnnual report
「As a result, revenue from the healthcare-related business was ¥2,002 million, up 16.6% year on year, and segment profit was ¥333 million, up 54.7%.」
For the nine months ended Q3, the healthcare-related business posted revenue of ¥2,002 million and segment profit of ¥333 million, with both revenue and profit increasing year on year. - FY2024-Q2AdvancedAnnual report
「As a result, revenue from the healthcare-related business was ¥1,292 million, up 11.9% year on year, and segment profit was ¥194 million, up 40.9%.」
The healthcare-related business posted revenue of ¥1,292 million and segment profit of ¥194 million, representing year-on-year increases in both revenue and profit. - FY2023AdvancedAnnual report
「Revenue from the healthcare-related business was ¥2,286 million, up 19.8% year on year, and segment profit was ¥248 million, up 40.0%.」
For the full year, the healthcare-related business posted revenue of ¥2,286 million and segment profit of ¥248 million, with continued growth in both revenue and profit. - FY2023-Q3AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥1,716 million, up 21.5% year on year, and segment profit was ¥215 million, up 70.9%.」
For the nine months ended Q3, the healthcare-related business posted revenue of ¥1,716 million and segment profit of ¥215 million, representing year-on-year increases in both revenue and profit. - FY2023-Q2AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥1,154 million, up 23.1% year on year, and operating profit was ¥137 million, up 70.0%.」
For the cumulative second quarter, revenue from the medical-related business was ¥1,154 million and operating profit was ¥137 million, representing year-on-year increases in both revenue and profit. - FY2023-Q1AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥570 million, up 28.3% year on year, and operating profit was ¥71 million, up 122.4%.」
Revenue from the medical-related business was ¥570 million and operating profit was ¥71 million, representing year-on-year revenue growth and higher operating profit. - FY2022AdvancedAnnual report
「Revenue from the medical-related business was ¥1,909 million, up 16.8% year on year, and operating profit was ¥177 million, up 157.4%.」
For the full year, revenue from the medical-related business was ¥1,909 million and operating profit was ¥177 million, indicating increased revenue, higher profit and progress in its contribution to earnings. - FY2022-Q1AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥444 million, up 15.6% year on year, and segment profit was ¥32 million, up 19.5%.」
Both revenue and segment profit from the medical-related business increased year on year, recovering from the decline in earnings levels in the previous fiscal year. - FY2021WorsenedAnnual report
「Revenue from the medical-related business was ¥1,635 million, down 13.2% year on year, and operating profit was ¥68 million, down 79.2%.」
Although the medical-related business remained profitable, full-year revenue decreased 13.2% year on year and operating profit decreased 79.2%, resulting in a lower level of earnings. - FY2021-Q3WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥1,243 million, down 13.1% year on year, and segment profit was ¥85 million, down 69.4%.」
Although the medical-related business remained profitable, revenue decreased 13.1% year on year and segment profit decreased 69.4%, resulting in a lower level of earnings. - FY2021-Q2WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥827 million, down 10.8% year on year, and segment profit was ¥51 million, down 74.5%.」
Although the medical-related business remained profitable, revenue decreased 10.8% year on year and segment profit decreased 74.5%, resulting in a lower level of earnings. - FY2021-Q1WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥384 million, down 1.9% year on year, and segment profit was ¥26 million, down 69.3%.」
Although the medical-related business remained profitable, revenue decreased 1.9% year on year and segment profit decreased 69.3%, resulting in a lower level of earnings. - FY2020AdvancedAnnual report
「Revenue from the medical-related business was ¥1,883 million, up 49.9% year on year, and operating profit was ¥331 million, up 243.4%.」
Revenue and operating profit from the medical-related business increased substantially for the full year, indicating progress in its contribution to earnings. - FY2020-Q3AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥1,430 million, up 55.6% year on year, and operating profit was ¥278 million, up 317.0%.」
Revenue from the medical-related business was ¥1,430 million and operating profit was ¥278 million, representing year-on-year increases of 55.6% and 317.0%, respectively, as earnings continued to improve. - FY2020-Q2AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥928 million, up 54.8% year on year, and operating profit was ¥201 million, up 352.1%.」
Revenue from the medical-related business was ¥928 million and operating profit was ¥201 million, representing year-on-year increases of 54.8% and 352.1%, respectively. - FY2020-Q1AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥392 million, up 45.6% year on year, and operating profit was ¥87 million, up 521.5%.」
Revenue from the medical-related business increased 45.6% year on year, while operating profit was ¥87 million, up 521.5%, indicating progress in earnings improvement. - FY2019-Q3AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥919 million, up 34.0% year on year, and operating profit was ¥66 million, compared with a loss of ¥13 million in the same period of the previous year.」
Revenue from the medical-related business increased 34.0% year on year, and the business improved from an operating loss of ¥13 million in the same period of the previous year to operating profit of ¥66 million. - FY2019-Q2AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥599 million, up 34.5% year on year, and operating profit was ¥44 million, compared with a loss of ¥5 million in the same period of the previous year.」
The medical-related business turned from an operating loss of ¥5 million in the same period of the previous year to operating profit of ¥44 million, while revenue also increased 34.5% year on year. - FY2019-Q1AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥269 million, up 31.0% year on year, and operating profit was ¥14 million, compared with a loss of ¥7 million in the same period of the previous year.」
The medical-related business turned from an operating loss in the same period of the previous year to operating profit, while revenue also increased 31.0% year on year. - FY2018WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥981 million, up 18.0% year on year, and operating loss was ¥23 million, compared with profit of ¥30 million in the previous fiscal year.」
Although revenue from the medical-related business increased, full-year results turned from operating profit of ¥30 million in the previous fiscal year to an operating loss of ¥23 million. - FY2018-Q3WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥685 million, up 8.0% year on year, and operating loss was ¥13 million, compared with profit of ¥30 million in the same period of the previous year.」
Although revenue from the medical-related business increased, it turned from operating profit of ¥30 million in the same period of the previous year to an operating loss of ¥13 million. - FY2018-Q2WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥445 million, up 6.1% year on year, and operating loss was ¥5 million, compared with profit of ¥21 million in the same period of the previous year.」
The medical-related business turned from operating profit of ¥21 million in the same period of the previous year to an operating loss of ¥5 million in the cumulative second quarter. - FY2018-Q1WorsenedAnnual report
「As a result, revenue from the medical-related business was ¥205 million, up 0.4% year on year, and operating loss was ¥7 million, compared with profit of ¥2 million in the same period of the previous year.」
The medical-related business turned from operating profit in the same period of the previous year to an operating loss of ¥7 million in the current quarter. - FY2017RestatedAnnual report
「As a result, revenue from the medical-related business was ¥832 million, up 1.3% year on year, and operating profit was ¥30 million, compared with a loss of ¥35 million in the previous fiscal year.」
The full-year results confirmed that the medical-related business had turned from an operating loss in the previous year to operating profit. - FY2017-Q3AdvancedAnnual report
「As a result, revenue from the medical-related business was ¥634 million, up 5.3% year on year, and operating profit was ¥30 million, compared with a loss of ¥34 million in the same period of the previous year.」
Following the previous quarter, when the medical-related business turned from an operating loss in the same period of the previous year to operating profit, operating profit was ¥30 million for the cumulative third quarter. - FY2017-Q2First statedAnnual report
「Revenue from the medical-related business was ¥420 million, up 3.5% year on year, and operating profit was ¥21 million, compared with an operating loss of ¥13 million in the same period of the previous year.」
The medical-related business swung from an operating loss in the same period of the previous year to operating profit of ¥21 million in the cumulative period through the current quarter.